BDNF Gene Mutation May Speed Up Memory Loss in Alzheimer's

This article originally appeared here.
Share this content:
<i>BDNF</i> Gene Mutation May Speed Up Memory Loss in Alzheimer's
BDNF Gene Mutation May Speed Up Memory Loss in Alzheimer's

THURSDAY, May 4, 2017 (HealthDay News) -- A gene mutation appears to speed up the loss of memory and cognitive skills in patients with Alzheimer's disease, according to a study published online May 3 in Neurology.

Researchers said the gene mutation -- called BDNF Val66Met allele, or the Met allele -- was pinpointed by following 1,023 people who were at risk of developing Alzheimer's disease. The researchers followed them for 13 years. The participants' average age was 55 at the start of the study. Blood samples were tested for the gene mutation. Memory and cognitive abilities were tested at the start of the study and at up to five visits during the study period.

The 32 percent of participants with the Met allele lost memory and cognitive skills more rapidly than those without the gene mutation, the researchers found. The decline was even quicker among those with both the Met allele and higher levels of β-amyloid.

"Because this gene can be detected before the symptoms of Alzheimer's start, and because this presymptomatic phase is thought to be a critical period for treatments that could delay or prevent the disease, it could be a great target for early treatments," study author Ozioma Okonkwo, Ph.D., of the University of Wisconsin School of Medicine in Madison, said in a news release from the American Academy of Neurology. "It is critical for future studies to further investigate the role that the BDNF gene and protein have in β-amyloid accumulation in the brain."

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

Cost-Effectiveness of PCSK9 Inhibitors Called Into Question

Cost-Effectiveness of PCSK9 Inhibitors Called Into Question

Researchers say price would have to be between $4,000 and $5,000 per year to be cost-effective

Vitamin B6, B12 Supplements May Up Risk of Lung Cancer in Men

Vitamin B6, B12 Supplements May Up Risk of ...

Increased odds only seemed to affect men or male smokers

Tablet Use Encourages Patients to Explore Diabetes Risk

Tablet Use Encourages Patients to Explore Diabetes Risk

Replacing magazines with tablets can help patients learn about diabetes risk, take preventive action

is free, fast, and customized just for you!

Already a member?

Sign In Now »